The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

rexahn.com

Founded Year

2001

Stage

IPO | IPO

Market Cap

0.04B

Stock Price

2.16

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals (NYSE:RNN) is a clinical stage biopharmaceutical company dedicated to developing targeted therapeutics for the treatment of cancer. The company's mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth.

Rexahn Pharmaceuticals Headquarter Location

15245 Shady Grove Road Suite 455

Rockville, Maryland, 20850,

United States

240-268-5300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Rexahn Pharmaceuticals Patents

Rexahn Pharmaceuticals has filed 12 patents.

The 3 most popular patent topics include:

  • Fluoroarenes
  • Amines
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/6/2018

2/25/2020

Fluoroarenes, Amines, Experimental cancer drugs, Pyridines, Carboxamides

Grant

Application Date

4/6/2018

Grant Date

2/25/2020

Title

Related Topics

Fluoroarenes, Amines, Experimental cancer drugs, Pyridines, Carboxamides

Status

Grant

Latest Rexahn Pharmaceuticals News

DNA Methyltransferase Inhibitor Drug Pipeline Market Research Report 2022 Featuring Rexahn Pharmaceuticals, SuperGen, & SignalRx Pharmaceuticals - ResearchAndMarkets.com

Feb 3, 2022

February 03, 2022 11:58 AM Eastern Standard Time "DNA Methyltransferase Inhibitor - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across DNA Methyltransferase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for DNA Methyltransferase Inhibitor Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for DNA Methyltransferase Inhibitor The report assesses the active DNA Methyltransferase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route. Scope of the Report Provides a snapshot of the therapeutics pipeline activity for DNA Methyltransferase Inhibitor Features the DNA Methyltransferase Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of DNA Methyltransferase Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across DNA Methyltransferase Inhibitor Key Topics Covered:

  • When was Rexahn Pharmaceuticals founded?

    Rexahn Pharmaceuticals was founded in 2001.

  • Where is Rexahn Pharmaceuticals's headquarters?

    Rexahn Pharmaceuticals's headquarters is located at 15245 Shady Grove Road, Rockville.

  • What is Rexahn Pharmaceuticals's latest funding round?

    Rexahn Pharmaceuticals's latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.